Dose-dense neoadjuvant bi-weekly nab-paclitaxel followed by epirubicin-cyclophosphamide versus bi-weekly docetaxel followed by epirubicin-cyclophosphamide in patients with HR+/HER2- early breast cancer: a multicentre, randomised, phase III trial
Breast Cancer Research and Treatment · 2026-11 · 220 (1)
DOI: 10.1007/s10549-026-08091-4 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 09.11.2026. Verfasst von Mingkun Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shanxi, 710032, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 38 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shanxi, 710032, China.
- Department of Surgical Oncology, Shaanxi Provincial People's hospital, Xi'an, Shanxi, 710068, China.
- Department of General Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, 710038, China.
- Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shanxi, 710032, China. ting_w100@126.com.
- Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shanxi, 710032, China. vascularzhang@163.com.
Zitieren
APA
Zhang, M., Qin, Y., Wan, J., Tian, Z., Zhang, Z., Zhu, X., Fan, D., Yang, L., Hou, L., Zhang, H., Zhao, G., Wang, T., & Zhang, J. (2026). Dose-dense neoadjuvant bi-weekly nab-paclitaxel followed by epirubicin-cyclophosphamide versus bi-weekly docetaxel followed by epirubicin-cyclophosphamide in patients with HR+/HER2- early breast cancer: a multicentre, randomised, phase III trial. Breast Cancer Research and Treatment, 220(1). https://doi.org/10.1007/s10549-026-08091-4
Vancouver
Zhang M, Qin Y, Wan J, Tian Z, Zhang Z, Zhu X, et al. Dose-dense neoadjuvant bi-weekly nab-paclitaxel followed by epirubicin-cyclophosphamide versus bi-weekly docetaxel followed by epirubicin-cyclophosphamide in patients with HR+/HER2- early breast cancer: a multicentre, randomised, phase III trial. Breast Cancer Research and Treatment. 2026;220(1). doi:10.1007/s10549-026-08091-4
BibTeX
@article{Zhang2026,
author = {Zhang, Mingkun and Qin, Yuan and Wan, Junhao and Tian, Zelin and Zhang, Ziyu and Zhu, Xulong and Fan, Dong and Yang, Liu and Hou, Lan and Zhang, Huan and Zhao, Ge and Wang, Ting and Zhang, Juliang},
title = {Dose-dense neoadjuvant bi-weekly nab-paclitaxel followed by epirubicin-cyclophosphamide versus bi-weekly docetaxel followed by epirubicin-cyclophosphamide in patients with HR+/HER2- early breast cancer: a multicentre, randomised, phase III trial},
journal = {Breast Cancer Research and Treatment},
year = {2026},
volume = {220},
number = {1},
doi = {10.1007/s10549-026-08091-4}
}
EUVIMED